Home > Boards > US OTC > Medical - Drugs > Roche Holding Ltd. (RHHBY)

With Patent Cliff Looming, 2 Potential Takeover Targets

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
pointofreturn Member Profile
Followed By 20
Posts 585
Boards Moderated 0
Alias Born 01/21/11
160x600 placeholder
FDA Approves Marketing of Roche Diagnostics MRSA Diagnostic Test Dow Jones News - 12/5/2019 1:10:00 PM
Genentech: FDA Approves Tecentriq Plus Chemotherapy for Some Non-Small Cell Lung Cancer Dow Jones News - 12/3/2019 7:21:00 PM
Genentech Gets FDA Priority Review for Risdiplam for Spinal Muscular Atrophy Dow Jones News - 11/25/2019 7:36:00 AM
FDA Accepts Avastin Biosimilar BLA From Biogen, Samsung BioLogics Venture Dow Jones News - 11/19/2019 8:45:00 AM
New Hope in the Battle Against Ovarian Cancer NetworkNewsWire - 11/5/2019 8:45:00 AM
Delivering Precision Medicine’s True Potential: Big Data, Artificial Intelligence Identify New Cancer Therapeutics NetworkNewsWire - 10/29/2019 8:45:00 AM
U.K.'s Competition Watchdog Opens Probe into Roche Takeover of Spark Therapeutics Dow Jones News - 10/22/2019 2:46:00 AM
Roche: Phase 3 Study of Tecentriq, Avastin Combination a Success Dow Jones News - 10/21/2019 1:44:00 AM
Roche Says Outlook Is Improving as Revenue Grows Dow Jones News - 10/16/2019 1:48:00 AM
Roche Holding: Results From Tecentriq Study in Bladder Cancer Positive Dow Jones News - 9/30/2019 11:20:00 AM
Genentech Gets FDA Approval for Rituxan in Children With Two Rare Blood Vessel Disorders Dow Jones News - 9/27/2019 2:32:00 PM
Genentech Says Data Positive From Tecentriq Lung Cancer Study Dow Jones News - 9/27/2019 11:20:00 AM
U.K. Regulator to Probe Roche's Acquisition of Spark Therapeutics Dow Jones News - 9/25/2019 2:54:00 AM
Gene Therapies with Potential to Conquer Tough-to-Tackle Breast Cancers NetworkNewsWire - 9/24/2019 8:45:00 AM
Genentech Gets FDA Breakthrough Designation for Gazyva in Lupus Nephritis Dow Jones News - 9/18/2019 6:40:00 AM
Genentech Receives FDA Accelerated Approval for Cancer Treatment Dow Jones News - 8/15/2019 4:36:00 PM
Roche Extends Offer Period for Spark Therapeutics Dow Jones News - 7/31/2019 1:48:00 AM
Roche: CHMP Backs Tecentriq in Extensive-Stage Small-Cell Lung Cancer Dow Jones News - 7/26/2019 10:46:00 AM
Roche Sales Boosted by New Drug Pipeline -- Update Dow Jones News - 7/25/2019 4:14:00 AM
Roche 1st Half Profit, Sales Grew; Raises Full-Year Sales Guidance Dow Jones News - 7/25/2019 1:46:00 AM
Sanofi Gets Exclusive Over-The-Counter Rights to Tamiflu in the US From Roche Dow Jones News - 7/23/2019 1:47:00 AM
AbbVie Says FDA Lifts Partial Hold on Phase 3 Trial Dow Jones News - 6/24/2019 9:38:00 AM
Exelixis: Phase 3 Combination Study for Melanoma Didn't Meet Primary Endpoint Dow Jones News - 6/20/2019 7:37:00 PM
Genentech Gets FDA Priority Review For Rituxan in Children With Rare Blood Vessel Disorders Dow Jones News - 6/12/2019 6:48:00 AM
Genentech's Gazyva Meets Main Endpoints in Lupus Nephritis Study Dow Jones News - 6/11/2019 7:25:00 AM
pointofreturn   Saturday, 03/01/14 02:04:35 PM
Re: None
Post # of 138 
With Patent Cliff Looming, 2 Potential Takeover Targets For Roche

What Can Roche Do About The Expiration?
One way to offset the risk of a patent cliff is to extend the life of the expiring drug through modification. Modification might involve combining a drug with another compound to improve efficacy, or simply altering the delivery of the drug. There are problems associated with these actions however. Conducting trials to seek enhanced efficacy can be costly and time consuming; further, there is no guarantee that a combination will be successful. Altering the delivery method necessitates improved release rates, which even if achieved offer no guarantee of approval and extended exclusivity.

Read more:

Theralese Technologies Inc. (TLTFF): Potential Target Number One

The first company that could be the target of a Roche deal in the next two years is Theralase, Inc. (TLT.V) (TLTFF). Theralase currently generates revenues from the sale of its cold laser technology, which practitioners use to simulate the healing process in patients with muscle damage. In addition to this however, Theralase is currently developing a type of cancer treatment, which uses lasers to activate compounds that, when activated, kill cancer cells.

Theralase (TLTFF) : A Prime Roche Target
Just found this article about a big pharma company, Roche, and two potential targets for it to acquire based on its 'patent cliff', particularly its expiring Herceptin sales...

A patent cliff is the decline in revenues a pharmaceutical company experiences when the patents on one or more of their protected compounds expires. The lack of patent protection opens up the market to generic alternatives, which generic drug manufacturers sell at a discount to the branded option. This reduced cost redirects revenues from the manufacturers (generally big pharma) that bore the cost of research and development.

During 2014, the patent cliff concept will expose a number of incumbent pharmaceutical companies to potential revenue redirection. One of those companies is Roche Holdings (RHHBY), with the European patent for the company's breast cancer drug, Herceptin, due for expiry. Roche's Herceptin sales totaled $6.07B during 2013, 16% of the company's total annual sales.


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist